Deutsch English Français

Kontakt

Registerüberwachung (E-Mail-Benachrichtigungen)

EP3056515

Europäisches Verfahren

Kurzhilfe

Wartungsmeldungen

Geplante Wartungsarbeiten

Regelmäßige Unterbrechungen:
zwischen 5.00 und 5.15 Uhr MEZ (Montag bis Sonntag).

Andere Unterbrechungen
Verfügbarkeit

2022.02.11

Mehr...

Kurzmeldungen

Italien schließt sich dem Vereinigten Register an

Nähere Informationen zum Vereinigten Register finden Sie hier.

2025-06-12

Mehr...

Themenbezogene Links

Notizen zu Neuerungen
Assistent zum Europäischen Patentregister
Handbuch zum Europäischen Patentregister (auf Englisch)
Europäisches Patentregister – Kurzanleitung
FAQ - Europäisches Patentregister
Vereinigtes Register (Flyer)
Globale Akte (Flyer)
Ereignisse im Register
Datenverfügbarkeit für Deep Links
Inhalt des Vereinigten Registers
Tour Patentinformation
Leitfaden zur fairen Nutzung

Auszug aus dem europäischen Patentregister

EP Übersicht: EP3056515

EP3056515 - VERFAHREN ZUR BEHANDLUNG VON DURCH CD47 VERMITTELTER PHAGOZYTOSE [Mit Rechtsklick auf diesen Link können Sie ein Bookmark anlegen.]
Status	Patent in geändertem Umfang aufrechterhalten Status aktualisiert am 18.07.2025 Datenbank zuletzt aktualisiert am 28.03.2026
Frühere	Patent erteilt Status aktualisiert am 15.03.2019
Frühere	Erteilung des Patents vorgesehen Status aktualisiert am 03.03.2019
Frühere	Prüfungsverfahren läuft Status aktualisiert am 05.05.2017
Letztes Ereignis Tooltip	18.07.2025	Patent aufrechterhalten (B2-Veröffentlichung)	veröffentlicht am 20.08.2025 [2025/34]
Anmelder	Für alle benannten Staaten The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386 Stanford, CA 94305-2038 / US
	[2019/38]
Frühere [2016/33]	Für alle benannten Staaten The Board of Trustees of The Leland Stanford Junior University Office of The General Counsel Building 170, 3rd Floor, Main Quad P.O. Box 20386 Stanford, CA 94305-2038 / US
Erfinder	01 / JAISWAL, Siddhartha Department of Pathology Massachusetts General Hospital Warren 245 55 Fruit St Boston MA 02114 / US
	02 / WEISSMAN, Irving L. 747 Santa Ynez Street Stanford, CA 97305 / US
	03 / JAMIESON, Catriona, Helen M. Moores University of California San Diego Cancer Center, MC 0820, 3855 Healty Science Drive La Jolla, CA 92093-0820 / US
	04 / MAJETI, Ravindra Stanford Institute for Stem Cell Bio and Regenerative Medicine 1050 Arastradero Road Building A Stanford, CA 94304 / US
	[2019/16]
Frühere [2016/33]	01 / JAISWAL, Siddhartha Department of Pathology Massachusetts General Hospital Warren 245 55 Fruit St Boston MA 02114 / US
	02 / WEISSMAN, Irving, L. 747 Santa Ynez Street Stanford, CA 97305 / US
	03 / JAMIESON, Catriona, Helen, M. Moores University of California San Diego Cancer Center, MC 0820, 3855 Healty Science Drive La Jolla, CA 92093-0820 / US
	04 / MAJETI, Ravindra Stanford Institute for Stem Cell Bio and Regenerative Medicine 1050 Arastradero Road Building A Stanford, CA 94304 / US
Vertreter	Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[2025/34]
Frühere [2016/33]	Chapman, Desmond Mark Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
Anmeldenummer, Anmeldetag	16160476.4	15.01.2009
	[2016/33]
Prioritätsnummer, Prioritätstag	US20080011324P	15.01.2008 Ursprünglich veröffentlichtes Format: US 11324 P
	US20080189786P	22.08.2008 Ursprünglich veröffentlichtes Format: US 189786 P
	[2016/33]
Anmeldesprache	EN
Verfahrenssprache	EN
Veröffentlichung	Art:	A1 Anmeldung mit Recherchenbericht
	Nr.:	EP3056515
	Datum:	17.08.2016
	Sprache:	EN
	[2016/33]
	Art:	B1 Patentschrift
	Nr.:	EP3056515
	Datum:	17.04.2019
	Sprache:	EN
	[2019/16]
	Art:	B2 Neue europäische Patentschrift
	Nr.:	EP3056515
	Datum:	20.08.2025
	Sprache:	EN
	[2025/34]
Recherchenbericht(e)	(Ergänzender) europäischer Recherchenbericht - versandt am:	EP	04.05.2016
Klassifikation	IPC:	A61K39/00, C07K16/28	[2019/11]
	CPC:	C07K16/2803 (EP,US); A61P35/02 (EP,US); C07K16/28 (US); C07K16/2896 (EP,US); C07K16/30 (US); C12N5/0093 (EP,US); (+) C12N5/0694 (EP,US); C12Q1/6886 (EP,US); G01N33/5011 (US); G01N33/57505 (EP,US); A61K2039/505 (EP,US); A61K2039/507 (US); C07K2317/24 (US); C07K2317/73 (US); C07K2317/75 (EP,US); C07K2317/76 (EP,US); C12Q2600/112 (EP,US); C12Q2600/136 (EP,US); G01N2500/04 (EP,US) (-)
	Frühere IPC [2016/33]	C07K16/28, A61K39/395, C07K16/46, A61K47/48, C07K16/18, C07K16/30, A61K39/00
Benannte Vertragsstaaten	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2017/12]
Frühere [2016/33]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
Bezeichnung der Erfindung	Deutsch:	VERFAHREN ZUR BEHANDLUNG VON DURCH CD47 VERMITTELTER PHAGOZYTOSE	[2016/33]
	Englisch:	METHODS FOR MANIPULATING PHAGOCYTOSIS MEDIATED BY CD47	[2016/33]
	Französisch:	PROCÉDÉS PERMETTANT DE MANIPULER LA PHAGOCYTOSE MÉDIÉE PAR CD47	[2016/33]
Prüfungsverfahren	15.03.2016	Prüfungsantrag gestellt [2016/33]
	23.05.2016	Absendung einer Mitteilung der Prüfungsabteilung (Frist: M04)
	03.10.2016	Erwiderung auf eine Mitteilung der Prüfungsabteilung
	25.04.2017	Absendung einer Mitteilung der Prüfungsabteilung (Frist: M06)
	19.09.2017	Erwiderung auf eine Mitteilung der Prüfungsabteilung
	20.11.2017	Einwendungen Dritter
	01.12.2017	Absendung einer Mitteilung der Prüfungsabteilung (Frist: M04)
	11.01.2018	Erwiderung auf eine Mitteilung der Prüfungsabteilung
	01.02.2018	Einwendungen Dritter
	23.03.2018	Absendung einer Mitteilung der Prüfungsabteilung (Frist: M06)
	28.09.2018	Erwiderung auf eine Mitteilung der Prüfungsabteilung
	26.10.2018	Absendung einer Mitteilung der Prüfungsabteilung (Frist: M04)
	12.11.2018	Erwiderung auf eine Mitteilung der Prüfungsabteilung
	16.11.2018	Einwendungen Dritter
	04.03.2019	Ankündigung der Patenterteilung
	05.03.2019	Erteilungsgebühr entrichtet
	05.03.2019	Veröffentlichungs-/Druckkostengebühr entrichtet
	05.03.2019	Eingang der Übersetzungen des Patentanspruchs/der Patentansprüche
Stammanmeldung(en) Tooltip	EP09701993.9 / EP2242512
Teilanmeldung(en)	EP19168096.6 / EP3539617
	EP22191294.2 / EP4144367
Einspruch (Einsprüche)	Einsprechende(r)	01 16.09.2019 21.01.2020 ADMISSIBLE König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Strasse 11 40545 Düsseldorf / DE Vertreter des Einsprechenden König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Düsseldorf, et al, et al Mönchenwerther Straße 11 40545 Düsseldorf / DE
		02 23.12.2019 13.10.2023 WITHDRAWN Arch Oncology, Inc. 2000 Sierra Point Parkway, Suite 700 Brisbane, CA 94005 / US Vertreter des Einsprechenden Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
		03 17.01.2020 24.01.2020 ADMISSIBLE Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK Vertreter des Einsprechenden J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB
		04 17.01.2020 24.01.2020 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Vertreter des Einsprechenden Mathys & Squire 32 London Bridge Street The Shard London SE1 9SG / GB
		[N/P]
	Frühere [2023/47]
	Einsprechende(r)	01 16.09.2019 21.01.2020 ADMISSIBLE König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Strasse 11 40545 Düsseldorf / DE Vertreter des Einsprechenden König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Düsseldorf, et al, et al Mönchenwerther Straße 11 40545 Düsseldorf / DE
		02 23.12.2019 13.10.2023 WITHDRAWN Arch Oncology, Inc. 2000 Sierra Point Parkway, Suite 700 Brisbane, CA 94005 / US Vertreter des Einsprechenden Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
		03 17.01.2020 24.01.2020 ADMISSIBLE Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK Vertreter des Einsprechenden J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB
		04 17.01.2020 24.01.2020 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Vertreter des Einsprechenden Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	Frühere [2023/42]
	Einsprechende(r)	01 16.09.2019 21.01.2020 ADMISSIBLE König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Strasse 11 40545 Düsseldorf / DE Vertreter des Einsprechenden König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Düsseldorf, et al, et al Mönchenwerther Straße 11 40545 Düsseldorf / DE
		02 23.12.2019 07.01.2020 ADMISSIBLE Arch Oncology, Inc. 2000 Sierra Point Parkway, Suite 700 Brisbane, CA 94005 / US Vertreter des Einsprechenden Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
		03 17.01.2020 24.01.2020 ADMISSIBLE Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK Vertreter des Einsprechenden J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB
		04 17.01.2020 24.01.2020 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Vertreter des Einsprechenden Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	Frühere [2022/30]
	Einsprechende(r)	01 16.09.2019 21.01.2020 ADMISSIBLE König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Strasse 11 40545 Düsseldorf / DE Vertreter des Einsprechenden König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Düsseldorf, et al, et al Mönchenwerter Straße 11 40545 Düsseldorf / DE
		02 23.12.2019 07.01.2020 ADMISSIBLE Arch Oncology, Inc. 2000 Sierra Point Parkway, Suite 700 Brisbane, CA 94005 / US Vertreter des Einsprechenden Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
		03 17.01.2020 24.01.2020 ADMISSIBLE Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK Vertreter des Einsprechenden J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB
		04 17.01.2020 24.01.2020 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Vertreter des Einsprechenden Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	Frühere [2020/09]
	Einsprechende(r)	01 16.09.2019 21.01.2020 ADMISSIBLE König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Strasse 11 40545 Düsseldorf / DE Vertreter des Einsprechenden König, Gregor Sebastian, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Straße 11 40545 Düsseldorf / DE
		02 23.12.2019 07.01.2020 ADMISSIBLE Arch Oncology, Inc. 2000 Sierra Point Parkway, Suite 700 Brisbane, CA 94005 / US Vertreter des Einsprechenden Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
		03 17.01.2020 ADMISSIBLE Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK Vertreter des Einsprechenden J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 17.01.2020 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Vertreter des Einsprechenden Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	Frühere [2020/07]
	Einsprechende(r)	01 16.09.2019 ADMISSIBLE König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Strasse 11 40545 Düsseldorf / DE Vertreter des Einsprechenden König, Gregor Sebastian, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Straße 11 40545 Düsseldorf / DE
		02 23.12.2019 07.01.2020 ADMISSIBLE Arch Oncology, Inc. 2000 Sierra Point Parkway, Suite 700 Brisbane, CA 94005 / US Vertreter des Einsprechenden Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
	Frühere [2019/43]
	Einsprechende(r)	01 16.09.2019 König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Strasse 11 40545 Düsseldorf / DE Vertreter des Einsprechenden König, Gregor Sebastian, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Straße 11 40545 Düsseldorf / DE
	03.02.2020	Aufforderung des Patentinhabers, eine Stellungnahme zum Einspruch einzureichen
	13.08.2020	Erwiderung des Patentinhabers auf den Einspruch (die Einsprüche)
	16.08.2023	Absage der mündlichen Verhandlung die für den 19.10.2023 geplant war
	19.10.2023	Termin der mündlichen Verhandlung
	17.10.2024	Rechtswirksamkeit der Zwischenentscheidung im Einspruchsverfahren
	18.10.2024	Absage der mündlichen Verhandlung die für den 21.10.2024 geplant war
	21.10.2024	Termin der mündlichen Verhandlung
	23.12.2024	Absendung der Zwischenentscheidung im Einspruchsverfahren
	23.12.2024	Niederschrift über die mündliche Verhandlung abgesandt
	19.05.2025	Absendung der Mitteilung über die Aufrechterhaltung des Patents in geändertem Umfang
Entrichtete Gebühren	Jahresgebühr
	15.03.2016	Jahresgebühr entrichtet Patentjahr 03
	15.03.2016	Jahresgebühr entrichtet Patentjahr 04
	15.03.2016	Jahresgebühr entrichtet Patentjahr 05
	15.03.2016	Jahresgebühr entrichtet Patentjahr 06
	15.03.2016	Jahresgebühr entrichtet Patentjahr 07
	15.03.2016	Jahresgebühr entrichtet Patentjahr 08
	11.01.2017	Jahresgebühr entrichtet Patentjahr 09
	15.01.2018	Jahresgebühr entrichtet Patentjahr 10
	15.01.2019	Jahresgebühr entrichtet Patentjahr 11
Ausschluss der ausschließlichen Tooltip Zuständigkeit des Einheitlichen Patentgerichts	Zu den entsprechenden Daten siehe das Register des Einheitlichen Patentgerichts
	Die Verantwortung für die Richtigkeit, Vollständigkeit oder Qualität der unter dem Link angezeigten Daten liegt allein beim Einheitlichen Patentgericht.
Erlöschen während des Einspruchsverfahrens Tooltip	HU	15.01.2009
	CY	17.04.2019
	CZ	17.04.2019
	EE	17.04.2019
	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	MK	17.04.2019
	MT	17.04.2019
	PL	17.04.2019
	RO	17.04.2019
	SI	17.04.2019
	SK	17.04.2019
	TR	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
	[2022/32]
Frühere [2022/28]	HU	15.01.2009
	CY	17.04.2019
	CZ	17.04.2019
	EE	17.04.2019
	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	MT	17.04.2019
	PL	17.04.2019
	RO	17.04.2019
	SI	17.04.2019
	SK	17.04.2019
	TR	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2020/26]	CZ	17.04.2019
	EE	17.04.2019
	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	PL	17.04.2019
	RO	17.04.2019
	SI	17.04.2019
	SK	17.04.2019
	TR	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2020/17]	CZ	17.04.2019
	EE	17.04.2019
	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	PL	17.04.2019
	RO	17.04.2019
	SK	17.04.2019
	TR	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2020/11]	CZ	17.04.2019
	EE	17.04.2019
	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	PL	17.04.2019
	RO	17.04.2019
	SK	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2020/10]	CZ	17.04.2019
	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	PL	17.04.2019
	RO	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2020/09]	CZ	17.04.2019
	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	PL	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2019/52]	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	PL	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2019/51]	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	BG	17.07.2019
	GR	18.07.2019
Frühere [2019/50]	HR	17.04.2019
	LT	17.04.2019
	LV	17.04.2019
	GR	18.07.2019
Frühere [2019/47]	LT	17.04.2019
Angeführte Dokumente:	Recherche	[XI] EP1693385 (CHUGAI PHARMACEUTICAL CO LTD et al.)
		[I] US2007111238 (JAMIESON CATRIONA H M et al.)
		[X] PARTHA MANNA ET AL: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1026 - 1036, XP055030076, ISSN: 0008-5472 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-03-1708
		[A] Y. LIU ET AL: "Signal Regulatory Protein (SIRPalpha ), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 12, 15 March 2002 (2002-03-15), pages 10028 - 10036, XP055030073, ISSN: 0021-9258, DOI: 10.1074/jbc.M109720200 DOI: http://dx.doi.org/10.1074/jbc.M109720200
		RAVINDRA MAJETI1 ET AL: "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", DEVELOPMENTAL CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 138, no. 2, 23 July 2009 (2009-07-23), pages 286 - 299, XP002632714, ISSN: 1097-4172, [retrieved on 20090723], DOI: 10.1016/J.CELL.2009.05.045 DOI: http://dx.doi.org/10.1016/J.CELL.2009.05.045
		S. B. WILLINGHAM ET AL: "The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 17, 26 March 2012 (2012-03-26), pages 6662 - 6667, XP055029983, ISSN: 0027-8424, DOI: 10.1073/pnas.1121623109 DOI: http://dx.doi.org/10.1073/pnas.1121623109
		[PI] MAJETI RAVINDRA ET AL: "CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 1 November 2008 (2008-11-01), pages 284, XP009160228, ISSN: 0006-4971
		[A] PETTERSEN R F ET AL: "CD47 SIGNALS T CELL DEATH", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 162, 1 January 1999 (1999-01-01), pages 7031 - 7040, XP002940659, ISSN: 0022-1767
		X. W. ZHAO ET AL: "Is targeting of CD47-SIRP enough for treating hematopoietic malignancy?", BLOOD, vol. 119, no. 18, 3 May 2012 (2012-05-03), pages 4333 - 4334, XP055116565, ISSN: 0006-4971, DOI: 10.1182/blood-2011-11-391367 DOI: http://dx.doi.org/10.1182/blood-2011-11-391367
		[X] P. P. MANNA ET AL: "The Mechanism of CD47-Dependent Killing of T Cells: Heterotrimeric Gi-Dependent Inhibition of Protein Kinase A", THE JOURNAL OF IMMUNOLOGY, vol. 170, no. 7, 1 April 2003 (2003-04-01), pages 3544 - 3553, XP055116597, ISSN: 0022-1767, DOI: 10.4049/jimmunol.170.7.3544 DOI: http://dx.doi.org/10.4049/jimmunol.170.7.3544
		M. P. CHAO ET AL: "Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia", CANCER RESEARCH, vol. 71, no. 4, 15 February 2011 (2011-02-15), pages 1374 - 1384, XP055029988, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-2238 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-10-2238
		JAISWAL S ET AL: "Macrophages as mediators of tumor immunosurveillance", TRENDS IN IMMUNOLOGY, ELSEVIER LTD. * TRENDS JOURNALS, GB, vol. 31, no. 6, 1 June 2010 (2010-06-01), pages 212 - 219, XP027079216, ISSN: 1471-4906, [retrieved on 20100601], DOI: 10.1016/J.IT.2010.04.001 DOI: http://dx.doi.org/10.1016/j.it.2010.04.001
		X. W. ZHAO ET AL: "CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 45, 8 November 2011 (2011-11-08), pages 18342 - 18347, XP055055636, ISSN: 0027-8424, DOI: 10.1073/pnas.1106550108 DOI: http://dx.doi.org/10.1073/pnas.1106550108
	vom Anmelder	US6465247
		US95627901
		WO9910478
		US5985660
		MOTEGI S. ET AL., EMBO J., vol. 22, no. 11, pages 2634 - 2644
		HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
		AKASHI ET AL., NATURE, vol. 404, no. 6774, 2000, pages 193
		KONDO ET AL., CELL, vol. 91, no. 5, 1997, pages 661 - 7
		KONDO ET AL., ANNU REV IMMUNOL., vol. 21, 2003, pages 759 - 806
		CHEN ET AL., IMMUNOL REV, vol. 157, 1997, pages 41 - 51
		MORRISON ET AL., CELL, vol. 96, 1999, pages 737 - 49
		WAGERS; WEISSMAN, STEM CELLS, vol. 24, no. 4, 2006, pages 1087 - 94
		WRIGHT DE ET AL., J EXP MED, vol. 195, no. 9, 2002, pages 1145 - 54
		MIKAYE K ET AL., J EXP MED, vol. 173, no. 3, 1991, pages 599 - 607
		VALK ET AL., N ENGL J MED, vol. 350, 2004, pages 1617 - 1628
		BULLINGER ET AL., BLOOD, vol. 111, 2008, pages 4490 - 4495
		SUBRAMANIAN ET AL., BLOOD, vol. 107, 2006, pages 2548 - 2556
		MAJETI ET AL., CELL STEM CELL, vol. 1, 2007, pages 635 - 645
	sonstige	WO9904094
		PIETSCH ET AL.: "Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies", BLOOD CANCER J., vol. 7, no. 2, 2017, pages e536, XP055395279 DOI: http://dx.doi.org/10.1038/bcj.2017.7
		LUCY E. MTAYER, ANNA VILALTA, G.A. AMOS BURKE, GUY C. BROWN: "Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis", ONCOTARGET, vol. 8, no. 37, 2017, pages 60892 - 60903, XP055456424 DOI: http://dx.doi.org/10.18632/oncotarget.18492
		PIETSCH ET AL.: "Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies", BLOOD CANCER JOURNAL, vol. 7, 2017, XP055395279 DOI: http://dx.doi.org/10.1038/bcj.2017.7
		HAYLEY RUTGER: "Students draw a crowd to annual research and community health symposium", STANFORD SCHOOL OF MEDICINE NEWS, 20 May 2008 (2008-05-20), XP055532055, Retrieved from the Internet
	Einspruch	EP2111869
		EP1693385
		WO2004096133
		WO9940940
		EP1035132
		US2009000319
		WO9940940
		WO2004096133
		EP2111869
		WO2009131453
		EP1035132
		EP1693385
		US2007111238
		WO2014149477
		WO2011143624
		WO2014108483
		WO2009091601
		US1132408
		US18978608
		EP3056515
		WO2009091601
		US1132408
		US18978608
		EP1693385
		US2007111238
		EP2228772
		EP2111869
		EP1035132
		WO9940940
		EP1693385
		JP2007008895
		WO0166737
		US2004213792
		EP2111869
		US2007111238
		EP2212424
		MANNA ET AL.: "CD 47 mediates killing of breast tumor cells via Gi- dependent inhibition of protein kinase A", CANCER RESEARCH, vol. 64, 1 February 2004 (2004-02-01), pages 1026 - 1036, XP055030076, DOI: 10.1158/0008-5472.CAN-03-1708 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-03-1708
		KIM ET AL.: "Association of CD 47 with natural killer cell -mediated cytotoxicity of head-and-neck squamous cell carcinoma lines", TUMOR BIOLOGY, vol. 29, May 2008 (2008-05-01), pages 28 - 34, XP055347764 DOI: http://dx.doi.org/10.1159/000132568
		CHAO ET AL.: "Targeting CD 47 eliminates human acute myeloid leukemia stem cells", PRESENTATIONS AT THE STANFORD MEDICAL STUDENT RESEARCH SYMPOSIUM, 14 May 2008 (2008-05-14), pages 1 - 7, XP055348747
		RUTGER H., ET AL.: "Students draw a crowd to annual research and community health symposium", NEWS RELEASE FROM STANFORD SCHOOL OF MEDICINE, 21 May 2008 (2008-05-21), pages 1 - 5, XP055532055
		MAJETI ET AL.: "CD 47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", BLOOD, vol. 112, no. 11, 16 November 2008 (2008-11-16), pages 284, XP009160228
		OLDENBORG ET AL.: "Role of CD 47 as a marker of self on red blood cells", SCIENCE, vol. 288, 16 June 2000 (2000-06-16), pages 2051 - 2054, XP055304810, DOI: 10.1126/science.288.5473.2051 DOI: http://dx.doi.org/10.1126/science.288.5473.2051
		HAGMANN, A: "new way to keep immune cells in check", SCIENCE, vol. 288, no. 5473, 16 June 2000 (2000-06-16), pages 1945 - 1946, XP055345453
		ANONYMOUS: "Scientists discover new way to distinguish self from other", SCIENCE DAILY ARTICLE, 19 June 2000 (2000-06-19), XP055348264
		OLDENBORG ET AL.: "Cd47-Signal Regulatory Protein (Sirp) Regulates Fc and Complement ReceptorMediated Phagocytosis", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 193, no. 7, 2 April 2001 (2001-04-02), pages 855 - 862, XP055283803
		BLAZAR ET AL.: "Integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 194, no. 4, 20 August 2001 (2001-08-20), pages 541 - 549, XP055084225 DOI: http://dx.doi.org/10.1084/jem.194.4.541
		GARDAI ET AL.: "Cell -surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte", CELL, vol. 123, 21 October 2005 (2005-10-21), pages 321 - 334, XP002432361, DOI: 10.1016/j.cell.2005.08.032 DOI: http://dx.doi.org/10.1016/j.cell.2005.08.032
		OLDENBORG: "Role of CD 47 in erythroid cells and in autoimmunity", LEUKEMIA AND LYMPHOMA, vol. 45, no. 7, July 2004 (2004-07-01), pages 1319 - 1327, XP008060559, DOI: 10.1080/1042819042000201989 DOI: http://dx.doi.org/10.1080/1042819042000201989
		BROWN ET AL.: "Integrin-associated protein ( CD 47) and its ligands", TRENDS IN CELL BIOLOGY, vol. 11, no. 3, 1 March 2001 (2001-03-01), pages 130 - 135, XP002413983, DOI: 10.1016/S0962-8924(00)01906-1 DOI: http://dx.doi.org/10.1016/S0962-8924(00)01906-1
		TAKIZAWA ET AL.: "Macrophage tolerance: CD 47-SIRP-a-mediated signals matter", NATURE IMMUNOLOGY, vol. 8, no. 12, December 2007 (2007-12-01), pages 1287 - 1289, XP055094296, DOI: 10.1038/ni1207-1287 DOI: http://dx.doi.org/10.1038/ni1207-1287
		OLSSON ET AL.: "Platelet homeostasis is regulated by platelet expression of CD 47 under normal conditions and in passive immune thrombocytopenia", BLOOD, vol. 105, no. 9, 1 May 2005 (2005-05-01), pages 3577 - 3582, XP055347748, DOI: 10.1182/blood-2004-08-2980 DOI: http://dx.doi.org/10.1182/blood-2004-08-2980
		OLSSON ET AL.: "Target cell CD 47 regulates macrophage activation and erythrophagocytosis", TRANSFUSION CLINIQUE ET BIOLOGIQUE, vol. 13, no. 1- 2, 29 March 2006 (2006-03-29), pages 39 - 43, XP028032798, DOI: 10.1016/j.tracli.2006.02.013 DOI: http://dx.doi.org/10.1016/j.tracli.2006.02.013
		IDE ET AL.: "Role for CD 47-SIRPa signaling in xenograft rejection by macrophages", PNAS, vol. 104, no. 12, 20 March 2007 (2007-03-20), pages 5062 - 5066, XP055668087
		TAKENAKA ET AL.: "Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells", NATURE IMMUNOL, vol. 8, no. 12, December 2007 (2007-12-01), pages 1313 - 1323, XP055539168, DOI: 10.1038/ni1527 DOI: http://dx.doi.org/10.1038/ni1527
		SEIFFERT ET AL.: "Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD 47", BLOOD, vol. 94, no. 11, 1 December 1999 (1999-12-01), pages 3633 - 3643, XP000984772
		MANNA ET AL.: "The mechanism of CD 47-dependent killing of T Cells: heterotrimeric Gi-dependent inhibition of protein kinase A", THE JOURNAL OF IMMUNOLOGY, vol. 170, 1 April 2003 (2003-04-01), pages 3544 - 3553, XP055116597, DOI: 10.4049/jimmunol.170.7.3544 DOI: http://dx.doi.org/10.4049/jimmunol.170.7.3544
		REBRES ET AL.: "Novel CD 47-dependent intercellular adhesion modulates cell migration", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 205, no. 2, 5 May 2005 (2005-05-05), pages 182 - 193, XP055345445
		MATEO ET AL.: "CD 47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia", NATURE MEDICINE, vol. 5, no. 11, November 1999 (1999-11-01), pages 1277 - 1284, XP002942112, DOI: 10.1038/15233 DOI: http://dx.doi.org/10.1038/15233
		MATEO ET AL.: "Mechanisms of CD 47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organisation", BLOOD, vol. 100, no. 8, 14 June 2002 (2002-06-14), pages 2882 - 2890, XP055125010, DOI: 10.1182/blood-2001-12-0217 DOI: http://dx.doi.org/10.1182/blood-2001-12-0217
		SUBRAMANIAN ET AL.: "Species- and cell type-specific interactions between CD 47 and human SIRPa", BLOOD, vol. 107, no. 6, 15 November 2005 (2005-11-15), pages 2548 - 2556, XP002608759, DOI: 10.1182/blood-2005-04-1463 DOI: http://dx.doi.org/10.1182/blood-2005-04-1463
		MAWBY ET AL.: "Isolation and characterization of CD 47 glycoprotein: a 1 December 1994", BIOCHEM, vol. 304, 1999, pages 525 - 530, XP008037597
		MOTEGI ET AL.: "Role of the CD 47-SHPS-1 system in regulation of cell migration", THE EBMO JOURNAL, vol. 22, no. 11, 2 June 2003 (2003-06-02), pages 2634 - 2644, XP002481062, DOI: 10.1093/emboj/cdg278 DOI: http://dx.doi.org/10.1093/emboj/cdg278
		TAMOTO ET AL.: "Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer", CLIN CANCER RES., vol. 10, 1 June 2004 (2004-06-01), pages 3629 - 3638, XP055668078 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-04-0048
		CAMPBELL ET AL.: "An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains", CANCER RESEARCH, vol. 52, 1 October 1992 (1992-10-01), pages 5416 - 5420, XP055348255
	CHEN ET AL.: "Expression and activation of signal regulatory protein a on astrocytomas", CANCER RESEARCH, vol. 64, 1 January 2004 (2004-01-01), pages 117 - 127, XP055348732, DOI: 10.1158/0008-5472.CAN-3455-2 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-3455-2
	JAMIESON ET AL.: "Increased expression of CD 47 is a constant marker in mouse and human myeloid leukemias", BLOOD, vol. 106, no. 11, 16 November 2005 (2005-11-16), pages 1 - 5, XP055668075 DOI: http://dx.doi.org/10.1182/blood.V106.11.3260.3260
	UNO ET AL.: "Antitumor activity of a monoclonal antibody against CD 47 in xenograft models of human leukemia", ONCOLOGY REPORTS, vol. 17, no. 5, 1 May 2007 (2007-05-01), pages 11 89 - 11 94, XP055127957, DOI: 10.3892/or.17.5.1189 DOI: http://dx.doi.org/10.3892/or.17.5.1189
	TROUNSON: "Stem cells, plasticity and cancer - uncomfortable bed fellows", DEVELOPMENT, vol. 131, no. 12, June 2004 (2004-06-01), pages 2763 - 2768, XP055348759, DOI: 10.1242/dev.01233 DOI: http://dx.doi.org/10.1242/dev.01233
	CROKER ET AL.: "Cancer stem cells: implications for the progression and treatment of metastatic disease", J. CELL . MOL. MED., vol. 12, no. 2, 20 December 2007 (2007-12-20), pages 374 - 390, XP055668069 DOI: http://dx.doi.org/10.1111/j.1582-4934.2007.00211.x
	UCHENDU ET AL.: "Preliminary study on the role of protein kinase C in CD 47-mediated phosphatidylserine exposure pathway by Bric 126 in Jurkat T Cells", DER PHARMACIA LETTRE, vol. 9, no. 8, 13 September 2017 (2017-09-13), pages 18 - 28, XP055668186
	ZHANG ET AL.: "Targeting the cancer biomarker CD 47: a review on the diverse mechanisms of the CD 47 pathway in cancer treatment", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol. 16, no. 6, 2016, pages 658 - 667, XP055668169
	STROME ET AL.: "A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects", THE ONCOLOGIST, vol. 12, September 2007 (2007-09-01), pages 1084 - 1095, XP055052443, DOI: 10.1634/theoncologist.12-9-1084 DOI: http://dx.doi.org/10.1634/theoncologist.12-9-1084
	YOSHIDA ET AL.: "Interaction between Src homology 2 domain bearing protein tyrosine phosphatase substrate-1 and CD 47 mediates the adhesion of human B lymphocytes to nonactivated endothelial cells", J IMMUNOL, vol. 168, 1 April 2002 (2002-04-01), pages 3213 - 3220, XP002423402
	LIU, Y. ET AL.: "Signal Regulatory Protein (SIRPalpha ), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration"", J. BIOL. CHEM., vol. 277, no. 12, 2002, pages 10028 - 10036, XP055030073 DOI: http://dx.doi.org/10.1074/jbc.M109720200
	MATEO, V. ET AL.: "CD 47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia", NATURE MEDICINE, vol. 5, no. 11, 1999, pages 1277 - 1284, XP002942112 DOI: http://dx.doi.org/10.1038/15233
	OLDENBORG, P-A. ET AL.: "Role of CD 47 as a marker of self on red blood cells", SCIENCE, vol. 288, no. 5473, 2000, pages 2051 - 2054, XP055304810 DOI: http://dx.doi.org/10.1126/science.288.5473.2051
	BLAZAR, B. R. ET AL.: "Integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells", J. EXP. MED., vol. 194, no. 4, 2001, pages 541 - 549, XP055084225 DOI: http://dx.doi.org/10.1084/jem.194.4.541
	OLSSON, M. ET AL.: "Platelet homeostasis is regulated by platelet expression of CD 47 under normal conditions and in passive immune thrombocytopenia", BLOOD, vol. 105, no. 9, 2005, pages 3577 - 3582, XP055347748 DOI: http://dx.doi.org/10.1182/blood-2004-08-2980
	GARDAI, S. J. ET AL.: "Cell -surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte", CELL, vol. 123, no. 2, 2005, pages 321 - 334, XP002432361 DOI: http://dx.doi.org/10.1016/j.cell.2005.08.032
	OLDENBORG P-A. ET AL.: "Cd47-Signal Regulatory Protein (Sirp) Regulates Fc and Complement ReceptorMediated Phagocytosis", J. EXP. MED., vol. 193, no. 7, 2001, pages 855 - 862, XP055283803
	OLSSON, M. ET AL.: "Dose-dependent inhibitory effect of CD47 in macrophage uptake of IgG-opsonized murine erythrocytes", BIOCHEM. BIOPHYS. RES. COMM., vol. 352, 2007, pages 193 - 197, XP005724581 DOI: http://dx.doi.org/10.1016/j.bbrc.2006.11.002
	PLATT, N. ET AL.: "Recognizing death: the phagocytosis of apoptotic cells", TRENDS IN CELL BIOLOGY, vol. 8, 1998, pages 365 - 372, XP055673783 DOI: http://dx.doi.org/10.1016/S0962-8924(98)01329-4
	CAMPBELL, I. G. ET AL.: "An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains", CANCER RESEARCH, vol. 52, 1992, pages 5416 - 5420, XP055348255
	POELS, L. G. ET AL.: "Monoclonal Antibody Against Human Ovarian Tumor-Associated Antigens", J. NATL. CANCER INST., vol. 76, no. 5, 1986, pages 781 - 791, XP055663185
	KIKUCHI, Y. ET AL.: "A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 315, 2004, pages 912 - 918, XP004491573 DOI: http://dx.doi.org/10.1016/j.bbrc.2004.01.128
	UNO, S. ET AL.: "Antitumor activity of a monoclonal antibody against CD 47 in xenograft models of human leukemia", ONCOLOGY REPORTS, vol. 17, 2007, pages 1189 - 1194, XP055127957 DOI: http://dx.doi.org/10.3892/or.17.5.1189
	OLDENBORG, P-A. ET AL.: "Role of CD 47 in erythroid cells and in autoimmunity", LEUKEMIA & LYMPHOMA, vol. 45, no. 7, 2004, pages 1319 - 1327, XP008060559 DOI: http://dx.doi.org/10.1080/1042819042000201989
	MAJETI, R . ET AL.: "CD 47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", BLOOD, vol. 112, no. 2, 2008, pages 284, XP009160228
	"HL60", 6 January 2020 (2020-01-06), XP055673873, Retrieved from the Internet
	"L1210 cells", 06-10-2019, XP055673875, Retrieved from the Internet
	WEISSMAN, I. L.: "The E. Donnall Thomas Lecture: Normal and Neoplastic Stem Cells", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 14, 2008, pages 849 - 858, XP022940656 DOI: http://dx.doi.org/10.1016/j.bbmt.2008.05.003
	TAKIZAWA, H. ET AL.: "Macrophage tolerance: CD 47-SIRP-a-mediated signals matter", NATURE IMMUNOL, vol. 8, 2007, pages 1287 - 1289, XP055094296 DOI: http://dx.doi.org/10.1038/ni1207-1287
	VAN DEN BERG, T. K. ET AL.: "Innate immune 'self' recognition: a role for CD47-SIRP@a interactions in hematopoietic stem cell transplantation", TRENDS IN IMMUNOLOGY, vol. 29, no. 5, 2008, pages 203 - 206, XP022635428 DOI: http://dx.doi.org/10.1016/j.it.2008.02.004
	PIETSCH, E. C. ET AL.: "Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies", BLOOD CANCER JOURNAL, vol. 7, 2017, pages e536, XP055395279 DOI: http://dx.doi.org/10.1038/bcj.2017.7
	METAYER, L. E. ET AL.: "Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis", ONCOTARGET, vol. 8, no. 37, 2017, pages 60892 - 60903, XP055456424 DOI: http://dx.doi.org/10.18632/oncotarget.18492
	PETROVA, P. S. ET AL.: "TI - TTI-621 (SIRPFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding", CLIN. CANCER RES., vol. 23, no. 4, 2017, pages 1068 - 1079, XP055540513 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-16-1700
	KAUDER, S. E. ET AL.: "ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile", PLOS ONE, vol. 13, no. 8, 2018, pages e0201832, XP055635503 DOI: http://dx.doi.org/10.1371/journal.pone.0201832
	MANNA ET AL.: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, 2004, pages 1026 - 1036, XP055030076 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-03-1708
	MAJETI ET AL.: "CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", BLOOD : JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 112, 2008, pages 284, XP009160228
	CHAO ET AL.: "TARGETING CD47 ELIMINATES HUMAN ACUTE MYELOID LEUKEMIA STEM CELLS", MEETING ABSTRACT, TWENTY- FIFTH ANNUAL STANFORD MEDICAL STUDENT RESEARCH SYMPOSIUM & FIFTH ANNUAL POM POPULATION HEALTH SYMPOSIUM, 14 May 2008 (2008-05-14), XP055348747
	RUTQER: "Students draw a crowd to annual research and community health symposium", MEDICAL CENTER REPORT, XP055532055
	MATEO ET AL.: "CD47 LIGATION INDUCES CASPASE-INDEPENDENT CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA", NATURE MEDICINE, vol. 5, no. 11, 1999, pages 1277 - 1284, XP002942112 DOI: http://dx.doi.org/10.1038/15233
	GAO ET AL.: "Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 1, 1996, pages 21 - 24, XP002248145 DOI: http://dx.doi.org/10.1074/jbc.271.1.21
	VERNON-WILSON ET AL.: "CD47 IS A LIGAND FOR RAT MACROPHAGE MEMBRANE SIGNAL REGULATORY PROTEIN SIRP (OX41) AND HUMAN SIRPALPHA1", EUR. J. IMMUNOL., vol. 30, 2000, pages 2130 - 2137, XP000984773
	SUBRAMANIAN ET AL.: "Species- and cell type-specific interactions between CD47 and human SIRP[alpha]", BLOOD, vol. 107, no. 6, 2006, pages 2548 - 2556, XP002608759 DOI: http://dx.doi.org/10.1182/blood-2005-04-1463
	LIU ET AL.: "Signal Regulatory Protein (SIRPalpha ), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration", THE JOURNAL OF BIOLOQICAL CHEMISTRY, vol. 277, no. 12, 2002, pages 10028 - 10036, XP055030073 DOI: http://dx.doi.org/10.1074/jbc.M109720200
	POELS ET AL.: "Monoclonal Antibody Against Human Ovarian Tumor-Associated Antigens", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 76, no. 5, 1986, pages 781 - 791, XP055663185
	CAMPBELL ET AL.: "An Ovarian Tumor Marker with Homology to Vaccinia Virus Contains an IgV-like Region and Multiple Transmembrane Domains", CANCER RESEARCH, vol. 52, 1992, pages 5416 - 5420, XP055348255
	OLDENBORG ET AL.: "Role of CD47 as a Marker of Self on Red Blood Cells", SCIENCE, vol. 288, 2000, pages 2051 - 2054, XP055304810 DOI: http://dx.doi.org/10.1126/science.288.5473.2051
	OLDENBORG: "ROLE OF CD47 IN ERYTHROID CELLS AND IN AUTOIMMUNITY", LEUKEMIA & LYMPHOMA, vol. 45, no. 7, 2004, pages 1319 - 1327, XP008060559 DOI: http://dx.doi.org/10.1080/1042819042000201989
	BROWN ET AL.: "Integrin-associated protein (CD47) and its ligands", TRENDS IN CELL BIOLOGY, vol. 11, no. 3, 2001, pages 130 - 135, XP002413983 DOI: http://dx.doi.org/10.1016/S0962-8924(00)01906-1
	JAMIESON ET AL.: "Increased expression of CD47 is a constant marker in mouse and human myeloid leukemias", BLOOD, vol. 106, no. 11, 2005, pages 3260, XP008138745
	OLDENBORQ ET AL.: "Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice", BLOOD, vol. 99, no. 10, 2002, pages 3500 - 3504, XP055674279 DOI: http://dx.doi.org/10.1182/blood.V99.10.3500
	OLDENBORG ET AL.: "Cd47-Signal Regulatory Protein (Sirp) Regulates Fc and Complement ReceptorMediated Phagocytosis", J. EXP. MED., vol. 193, no. 7, 2001, pages 855 - 861, XP055283803
	WANQ ET AL.: "Attenuation of phagocytosis of xenogeneic cells by manipulating CD47", BLOOD, vol. 109, no. 2, 2007, pages 836 - 842, XP002608757, DOI: 10.1182/blood-2006-04-019794 DOI: http://dx.doi.org/10.1182/blood-2006-04-019794
	GARDAI ET AL.: "Cell-surface calreticulin initiates clearance of viable apoptotic cells through trans-activation of LRP on the phagocyte", CELL, vol. 123, 2005, pages 321 - 334, XP002432361 DOI: http://dx.doi.org/10.1016/j.cell.2005.08.032
	MATEO ET AL.: "Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization", BLOOD, vol. 100, no. 8, 2002, pages 2882 - 2890, XP055125010 DOI: http://dx.doi.org/10.1182/blood-2001-12-0217
	ARMANT ET AL.: "CD47 LIGATION SELECTIVELY DOWNREGULATES HUMAN INTERLEUKIN 12 PRODUCTION", J. EXP. MED., vol. 190, no. 8, 1999, pages 1175 - 1181, XP000984762 DOI: http://dx.doi.org/10.1084/jem.190.8.1175
	DEMEURE ET AL.: "CD47 Engagement Inhibits Cytokine Production and Maturation of Human Dendritic Cells", J IMMUNOL, vol. 164, 2000, pages 2193 - 2199, XP055674307 DOI: http://dx.doi.org/10.4049/jimmunol.164.4.2193
	AVICE ET AL.: "CD47 Ligation Selectively Inhibits the Development of Human Naive T Cells into Th1 Effectors", J IMMUNOL, vol. 165, 2000, pages 4624 - 4631, XP055674308 DOI: http://dx.doi.org/10.4049/jimmunol.165.8.4624
	AVICE ET AL.: "Role of CD47 in the Induction of Human Naive T Cell Anergy", J IMMUNOL, vol. 167, 2001, pages 2459 - 2468, XP055674312 DOI: http://dx.doi.org/10.4049/jimmunol.167.5.2459
	LATOUR ET AL.: "Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation.", J IMMUNOL, vol. 167, 2001, pages 2547 - 2554, XP002457665
	PFEIFFER ET AL.: "Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts", EUR. J. IMMUNOL., vol. 31, 2001, pages 3153 - 3164, XP055541184 DOI: http://dx.doi.org/10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0
	"Antiangiogenic Agents in Cancer Therapy", 1999, article TEICHER: "Antiangiogenic Agents in Cancer Therapy", pages: 185 - 203
	LIU ET AL.: "The Role of CD47 in Neutrophil Transmigration : INCREASED RATE OF MIGRATION CORRELATES WITH INCREASED CELL SURFACE EXPRESSION OF CD47", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 43, 2001, pages 40156 - 40166, XP055674346 DOI: http://dx.doi.org/10.1074/jbc.M104138200
	CONGOTE ET AL.: "The C-terminal 26-residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47", FEBS LETTERS, vol. 576, 2004, pages 343 - 347, XP004605712 DOI: http://dx.doi.org/10.1016/j.febslet.2004.09.035
	LI ET AL.: "Thrombospondin-1 Inhibits TCR-Mediated T Lymphocyte Early Activation", J IMMUNOL, vol. 166, 2001, pages 2427 - 2436, XP055674363 DOI: http://dx.doi.org/10.4049/jimmunol.166.4.2427
	SEIFFERT ET AL.: "Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47", BLOOD, vol. 94, no. 11, 1999, pages 3633 - 3643, XP000984772
	PETTERSEN ET AL.: "CD47 Signals T Cell Death", J IMMUNOL, vol. 162, 1999, pages 7031 - 7040, XP002942113
	KEY: "Macrophages in cancer metastases and their relevance to metastatic growth", CANCER AND METASTASIS REVIEWS, vol. 2, 1983, pages 75 - 88
	JONES ET AL.: "Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum", BR. J. CANCER, vol. 35, 1977, pages 519 - 527, XP055674367 DOI: http://dx.doi.org/10.1038/bjc.1977.85
	RUSSEL ET AL.: "Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 146, 1977, pages 1511 - 1520, XP055674372 DOI: http://dx.doi.org/10.1084/jem.146.6.1511
	LIOTTA ET AL.: "REDUCTION OF TUMOUR CELL ENTRY INTO VESSELS BY BCG-ACTIVATED MACROPHAGES", BR. J. CANCER, vol. 36, 1977, pages 639 - 641, XP055674374 DOI: http://dx.doi.org/10.1038/bjc.1977.242
	FIDLER: "Inhibition of Pulmonary Metastasis by Intravenous Injection of Specifically Activated Macrophages1", CANCER RESEARCH, vol. 34, 1974, pages 1074 - 1078, XP055674376
	"Bone Metastasis and Molecular Mechanisms: Pathophysiology", 2004, article SINGH ET AL.: "Chapter 6", pages: 87 - 108, XP055674382
	ITO ET AL.: "NOD/SCID/GAMMAcnull mouse: an excellent recipient mouse model for engraftment of human cells", BLOOD, vol. 100, no. 9, 2002, pages 3175 - 3182, XP002981771 DOI: http://dx.doi.org/10.1182/blood-2001-12-0207
	NOMURA ET AL., HUMANIZED MICE, 2008, pages 53 - 76
	GOSSEN ET AL.: "TIGHT CONTROL OF GENE EXPRESSION IN MAMMALIAN CELLS BY TETRACYCLINE-RESPONSIVE PROMOTERS", PROC. NATL. ACAD. SCI. USA ., vol. 89, no. 12, 1992, pages 5547 - 5551, XP000564458 DOI: http://dx.doi.org/10.1073/pnas.89.12.5547
	MATSUO ET AL.: "Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins (11;9) (q23;p22p23)", LEUKEMIA, vol. 11, 1997, pages 1469 - 1477, XP009502888 DOI: http://dx.doi.org/10.1038/sj.leu.2400768
	"Textbook of Breast Cancer: A Clinical Guide to Therapy", 2006, article BONADONNA ET AL.: "Textbook of Breast Cancer: A Clinical Guide to Therapy", pages: 81
	STROME ET AL.: "A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects", THE ONCOLOGIST, vol. 12, 2007, pages 1084 - 1095, XP055052443 * multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J. (1999) 384: 525-530 * DOI: http://dx.doi.org/10.1634/theoncologist.12-9-1084
	WEISKOPF ET AL.: "Engineered SIRP alpha Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies", SCIENCE, vol. 341, 2013, pages 88 - 91, XP002769489
	WEISKOPF ET AL.: "CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 7, 2016, pages 2610 - 2620, XP055480649 DOI: http://dx.doi.org/10.1172/JCI81603
	METAYER ET AL.: "Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis", ONCOTARGET, vol. 8, no. 3 7, 2017, pages 60892 - 60903, XP055456424 DOI: http://dx.doi.org/10.18632/oncotarget.18492
	PIETSCH ET AL.: "Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies", BLOOD CANCER JOURNAL, vol. 7, 2017, pages 1 - 8, XP055395279 DOI: http://dx.doi.org/10.1038/bcj.2017.7
	PARTHA MANNA, WILLIAM FRAZIER: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1026 - 1036, XP055030076, ISSN: 00085472, DOI: 10.1158/0008-5472.CAN-03-1708 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-03-1708
	Y. LIU ET AL: "Signal Regulatory Protein (SIRPalpha ), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 12, 15 March 2002 (2002-03-15), pages 10028 - 10036, XP055030073, ISSN: 00219258, DOI: 10.1074/jbc.M109720200 DOI: http://dx.doi.org/10.1074/jbc.M109720200
	MAJETI RAVINDRA ET AL: "CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", BLOOD , vol. 112, no. 11, 1 November 2008 (2008-11-01), US, pages 284, XP009160228, ISSN: 0006-4971
	E. M. VAN BEEK: "Signal Regulatory Proteins in the Immune System", THE JOURNAL OF IMMUNOLOGY, vol. 175, no. 12, 15 December 2005 (2005-12-15), pages 7781 - 7787, XP055348305, ISSN: 0022-1767, DOI: 10.4049/jimmunol.175.12.7781 DOI: http://dx.doi.org/10.4049/jimmunol.175.12.7781
	JAMIESON ET AL: "Increased expression of CD 47 is a constant marker in mouse and human myeloid leukemias", BLOOD, vol. 106, no. 11, 16 November 2005 (2005-11-16), pages 1 - 5, XP055668075 DOI: http://dx.doi.org/10.1182/blood.V106.11.3260.3260
	"Scientists Discover New Way To Distinguish Self From Other", SCIENCE DAILY, 19 June 2000 (2000-06-19), XP055348264
	PETER M. HENSON ET AL: "Apoptotic cell removal", CURRENT BIOLOGY, vol. 11, no. 19, 1 October 2001 (2001-10-01), GB, pages R795 - R805, XP055348314, ISSN: 0960-9822, DOI: 10.1016/S0960-9822(01)00474-2 DOI: http://dx.doi.org/10.1016/S0960-9822(01)00474-2
	G KROEMER ET AL: "Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009", CELL DEATH AND DIFFERENTIATION, vol. 16, no. 1, 1 January 2009 (2009-01-01), GB, pages 3 - 11, XP055348325, ISSN: 1350-9047, DOI: 10.1038/cdd.2008.150 DOI: http://dx.doi.org/10.1038/cdd.2008.150
	REBRES ET AL: "Novel CD47-Dependent lntercellular Adhesion Modulates Cell Migration", J. CELL. PHYSIOL., vol. 205, 1 January 2005 (2005-01-01), pages 182 - 193, XP055345445
	P.-A. OLDENBORG: "Role of CD47 as a Marker of Self on Red Blood Cells", SCIENCE, vol. 288, no. 5473, 16 June 2000 (2000-06-16), US, pages 2051 - 2054, XP055304810, ISSN: 0036-8075, DOI: 10.1126/science.288.5473.2051 DOI: http://dx.doi.org/10.1126/science.288.5473.2051
	HAGMANN: "A New Way to Keep Immune Cells in Check", SCIENCE, vol. 288, no. 5473, 16 June 2000 (2000-06-16), pages 1945 - 1946, XP055345453
	PER-ARNE OLDENBORG ET AL: "Cd47-Signal Regulatory Protein (Sirp) Regulates Fc and Complement ReceptorMediated Phagocytosis", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 193, no. 7, pages 855 - 861, XP055283803, Retrieved from the Internet [retrieved on 20160627]
	GARDAI S.J, ET AL: "Cell-surface calreticulin initiates clearance of viable apoptotic cells through trans-activation of LRP on the phagocyte.", CELL, ELSEVIER, vol. 123, 21 October 2005 (2005-10-21), AMSTERDAM, NL, pages 321 - 334, XP002432361, ISSN: 0092-8674, DOI: 10.1016/j.cell.2005.08.032 DOI: http://dx.doi.org/10.1016/j.cell.2005.08.032
	MATEO V ET AL: "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia.", NATURE MEDICINE, vol. 5, no. 11, 1 November 1999 (1999-11-01), New York, pages 1277 - 1284, XP002163073, ISSN: 1078-8956, DOI: 10.1038/15233 DOI: http://dx.doi.org/10.1038/15233
	V. MATEO ET AL: "Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization", BLOOD, vol. 100, no. 8, 26 September 2002 (2002-09-26), pages 2882 - 2890, XP055125010, ISSN: 00064971, DOI: 10.1182/blood-2001-12-0217 DOI: http://dx.doi.org/10.1182/blood-2001-12-0217
	SEIFFERT ET AL., BLOOD, vol. 94, 1999, pages 3633 - 3643, XP000984772
	SUBRAMANIAN ET AL., BLOOD, vol. 107, 2006, pages 2548 - 2556, XP002608759 DOI: http://dx.doi.org/10.1182/blood-2005-04-1463
	BROWN ET AL., TRENDS IN CELL BIOL., vol. 11, 2001, pages 130 - 135, XP002413983 DOI: http://dx.doi.org/10.1016/S0962-8924(00)01906-1
	ROBERT W KARR, CHARACTERISATION OF CD 47 ANTIBODIES, 20 June 2017 (2017-06-20)
	VAN DEN BERG ET AL., TRENDS IMMUNOL., vol. 29, 2008, pages 203 - 206, XP022635428 DOI: http://dx.doi.org/10.1016/j.it.2008.02.004
	OLSSON ET AL., BLOOD, vol. 105, 2005, pages 3577 - 3582, XP055347748 DOI: http://dx.doi.org/10.1182/blood-2004-08-2980
	OLDENBORG ET AL., LEUKEMIA & LYMPHOMA, vol. 45, 2004, pages 1319 - 1327, XP008060559 DOI: http://dx.doi.org/10.1080/1042819042000201989
	BLAZAR ET AL., J. EXP. MEDICINE, vol. 194, 2001, pages 541 - 549, XP055084225 DOI: http://dx.doi.org/10.1084/jem.194.4.541
	CHAO ET AL.: "Abstract from Twenty-Fifth Annual Stanford Medical Student Research Symposium", 2008
	TAKIZAWA ET AL., NATURE IMMUNOL., vol. 8, 2007, pages 1287 - 1289, XP055094296 DOI: http://dx.doi.org/10.1038/ni1207-1287
	LATOUR ET AL., J. IMMUNOLOGY, vol. 167, 2001, pages 2547 - 2554, XP002457665
	WANG ET AL., BLOOD, vol. 109, 2007, pages 836 - 842, XP002608757 DOI: http://dx.doi.org/10.1182/blood-2006-04-019794
	VERNON-WILSON ET AL., EUR J IMMUNOL, vol. 30, 2000, pages 2130 - 2137, XP000984773
	NEWS RELEASE FROM STANFORD SCHOOL OF MEDICINE WEBSITE, 21 May 2008 (2008-05-21)
	BARAZI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 45, 2002, pages 42859 - 42866, XP002468585 DOI: http://dx.doi.org/10.1074/jbc.M206849200
	KUROSAKA ET AL., J. IMMUNOL, vol. 171, 2003, pages 4672 - 4679, XP55673999
	TUZMAN: "Eat this, don't eat that: CD 47 companies", BIOCENTURY, 2019, XP55673996
	ZHAO ET AL., BLOOD, vol. 119, 2012, pages 4333 - 4335, XP055116565 DOI: http://dx.doi.org/10.1182/blood-2011-11-391367
	PETTERSEN ET AL., J. IMMUNOLOGY, vol. 162, 1999, pages 7031 - 7040, XP002940659
	CHRISTIANSEN ET AL., MOL. CANCER THER., vol. 3, 2004, pages 1493 - 1501, XP007901437
	ZHANG ET AL., CELL RESEARCH, vol. 17, 2007, pages 89 - 99, XP55674003
	CRUZ ET AL., BIOLOGICS: TARGETS AND THERAPY, vol. 13, 2019, pages 33 - 51, XP55674009
	WEISKOPF ET AL., J CLIN INVEST., vol. 126, no. 7, 2016, pages 2610 - 2620, XP055480649 DOI: http://dx.doi.org/10.1172/JCI81603
	WEISKOPF ET AL., SCIENCE, vol. 341, 2013, pages 88 - 91, XP002745510 DOI: http://dx.doi.org/10.1126/science.1238856
	METAYER ET AL., ONCOTARGET, vol. 8, no. 37, 2017, pages 60892 - 60903, XP055456424 DOI: http://dx.doi.org/10.18632/oncotarget.18492
	PIETSCH ET AL., BLOOD CANCER JOURNAL, vol. 7, 2017, pages e536, XP055538876 DOI: http://dx.doi.org/10.1038/bcj.2017.7
	RAETZ ET AL., PEDIATR BLOOD CANCER, vol. 47, 2006, pages 130 - 140, XP055348724 DOI: http://dx.doi.org/10.1002/pbc.20550
	TAKIMOTO C.H., CHAO M.P., GIBBS C., MCCAMISH M.A., LIU J., CHEN J.Y., MAJETI R., WEISSMAN I.L.: "The Macrophage Do not eat me signal, CD47, is a clinically validated cancer immunotherapy target", ANNALS OF ONCOLOGY, vol. 30, no. 3, 1 March 2019 (2019-03-01), pages 486 - 489, XP093108437, ISSN: 0923-7534, DOI: 10.1093/annonc/mdz006 DOI: http://dx.doi.org/10.1093/annonc/mdz006
	QU TAILONG, LI BAIYONG, WANG YIFEI: "Targeting CD47/SIRP[alpha] as a therapeutic strategy, where we are and where we are headed", BIOMARKER RESEARCH, BIOMED CENTRAL LTD, vol. 10, 13 April 2022 (2022-04-13), pages 1 - 18, XP093028950, DOI: 10.1186/s40364-022-00373-5 DOI: http://dx.doi.org/10.1186/s40364-022-00373-5
	WANG YUCHEN, ZHAO CHENXUAN, LIU YANG, WANG CHAO, JIANG HAOJIE, HU YIQIAO, WU JINHUI: "Recent Advances of Tumor Therapy Based on the CD47-SIRP Axis", MOLECULAR PHARMACEUTICS, AMERICAN CHEMICAL SOCIETY, US, vol. 19, no. 5, 2 May 2022 (2022-05-02), US , pages 1273 - 1293, XP093078337, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.2c00073 DOI: http://dx.doi.org/10.1021/acs.molpharmaceut.2c00073
	KAUR SUKHBIR, CICALESE KYLE V, BANERJEE RAJDEEP, ROBERTS DAVID D: "Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment", ANTIBODY THERAPEUTICS, vol. 3, no. 3, 25 July 2020 (2020-07-25), pages 179 - 192, XP055805185, DOI: 10.1093/abt/tbaa017 DOI: http://dx.doi.org/10.1093/abt/tbaa017
	LIU YUE, WANG YANJIN, YANG YANRONG, WENG LINJUN, WU QI, ZHANG JIN, ZHAO PENGCHENG, FANG LAN, SHI YUFENG, WANG PING: "Emerging phagocytosis checkpoints in cancer immunotherapy", SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 8, no. 1, 7 March 2023 (2023-03-07), pages 1 - 42, XP093108444, ISSN: 2059-3635, DOI: 10.1038/s41392-023-01365-z DOI: http://dx.doi.org/10.1038/s41392-023-01365-z
	LIU MENGMENG, LIU LINA, SONG YONGPING, LI WEI, XU LINPING: "Targeting macrophages: a novel treatment strategy in solid tumors", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 20, no. 1, 12 December 2022 (2022-12-12), pages 586, XP093112866, DOI: 10.1186/s12967-022-03813-w DOI: http://dx.doi.org/10.1186/s12967-022-03813-w
	NARLA RAMA KRISHNA; MODI HARDIK; BAUER DANIEL; ABBASIAN MAHAN; LEISTEN JIM; PICCOTTI JOSEPH R.; KOPYTEK STEPHAN; ECKELMAN BRENDAN : "Modulation of CD47-SIRP innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody", CANCER IMMUNOLOGY IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 71, no. 2, 10 July 2021 (2021-07-10), Berlin/Heidelberg , pages 473 - 489, XP037673283, ISSN: 0340-7004, DOI: 10.1007/s00262-021-03010-6 DOI: http://dx.doi.org/10.1007/s00262-021-03010-6
	OZOLS ROBERT F: "Systemic therapy for ovarian cancer: current status and new treatments.", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, vol. 33, no. 2 Sppl. 6, 1 April 2006 (2006-04-01), US , pages S3 - S11, XP009148909, ISSN: 0093-7754, DOI: 10.1053/j.seminoncol.2006.03.011 DOI: http://dx.doi.org/10.1053/j.seminoncol.2006.03.011
	REARDON DAVID A., WEN PATRICK Y.: "Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents", THE ONCOLOGIST, vol. 11, no. 2, 1 February 2006 (2006-02-01), pages 152 - 164, XP093112867, ISSN: 1083-7159, DOI: 10.1634/theoncologist.11-2-152 DOI: http://dx.doi.org/10.1634/theoncologist.11-2-152
	ANONYMOUS: "Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)", CLINICALTRIALS.GOV IDENTIFIER: NCT05169944, 27 December 2021 (2021-12-27), XP093112873, Retrieved from the Internet [retrieved on 20231216]
	ANONYMOUS: "A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas", CLINICALTRIALS.GOV V IDENTIFIER: NCT04306224, 12 March 2020 (2020-03-12), XP093112872, Retrieved from the Internet [retrieved on 20231216]
	ANONYMOUS: "Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers", CLINICALTRIALS.GOV IDENTIFIER: NCT05192512, 14 January 2022 (2022-01-14), XP093112871, Retrieved from the Internet [retrieved on 20231216]
	"Orphanet encyclopedia", 1 May 2003, article DE SAINT-BASILE GENEVIEVE: "Wiskott-Aldrich syndrome", pages: 1 - 4, XP093112870
	ANONYMOUS: "Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer", CLINICAL TRIALS.GOV IDENTIFIER: NCT04958785, 12 July 2021 (2021-07-12), XP093112869, Retrieved from the Internet [retrieved on 20231216]
	ANONYMOUS: "Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)", CLINICAL TRIALS.GOV IDENTIFIER: NCT04854499, 22 April 2021 (2021-04-22), XP093112868, Retrieved from the Internet [retrieved on 20231216]

Das EPA übernimmt keine Gewähr für die Richtigkeit von Daten, die aus anderen Behörden stammen, und schließt insbesondere jegliche Garantie dafür aus, dass solche Daten vollständig, aktuell oder für bestimmte Zwecke geeignet sind.